Roberts Lesley, Alexander Carla-Maria, Monteil Michele, Manjunath Madhura, Mohammed Emile, Wilson Valerie, Wilson Stefan
Nephrology and Internal Medicine, Trinidad and Tobago.
Faculty of Medical Sciences, The University of The West Indies, St. Augustine, Trinidad and Tobago.
Vaccine X. 2024 Apr 20;18:100487. doi: 10.1016/j.jvacx.2024.100487. eCollection 2024 Jun.
This study compares the humoral immune response of a cohort of renal transplant recipients (RTRs), in Trinidad & Tobago following two-dose primary immunization with non-mRNA vaccines amidst the COVID-19 pandemic. RTRs along with healthy, age-and gender-matched controls received either the adenoviral vector vaccine, AstraZeneca-Vaxzevria (AZ) or the inactivated vaccine, Beijing CNBG-BBIBP- CorV/Sinopharm (SP). Samples were taken after completion of a two-dose primary immunization during the period November 2021 to December 2021, at a mean interval of 138 days following immunization. 38/72 RTRs (53 %) failed to generate any protective antibody responses, compared with 7/73 participants, approximately 10 % in the healthy, age and gender-matched control group. In the RTRs, there was no significant correlation of their antibody concentration with either the timing of sample collection or the interval since transplantation. The study provides necessary information about the humoral response after two- doses of non-mRNA vaccines in a group of transplant recipients.
本研究比较了特立尼达和多巴哥一群肾移植受者（RTR）在新冠疫情期间接种两剂非mRNA疫苗进行初次免疫后的体液免疫反应。RTR与年龄和性别匹配的健康对照者分别接种腺病毒载体疫苗阿斯利康-瓦克泽维里亚（AZ）或灭活疫苗北京科兴中维-克尔来福/国药集团（SP）。在2021年11月至2021年12月期间完成两剂初次免疫后采集样本，免疫后平均间隔138天。38/72名RTR（53%）未能产生任何保护性抗体反应，而在年龄和性别匹配的健康对照组中，7/73名参与者（约10%）未产生反应。在RTR中，其抗体浓度与样本采集时间或移植后的间隔时间均无显著相关性。该研究提供了一组移植受者接种两剂非mRNA疫苗后体液反应的必要信息。
